New pathways in immune stimulation: targeting OX40

Eggermont, 2018, Adjuvant pembrolizumab versus placebo in resected stage III melanoma, N Engl J Med Overseas Ed, 378, 1789, 10.1056/NEJMoa1802357 Weber, 2017, Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma, N Engl J Med, 377, 1824, 10.1056/NEJMoa1709030 2019, Durvalumab after chemoradiotherapy in stage III Non–Small-Cell lung cancer, N Engl J Med, 380, 989, 10.1056/NEJMc1900407 Gao, 2016, Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy, Cell, 167, 397, 10.1016/j.cell.2016.08.069 Shin, 2017, Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations, Cancer Discov, 7, 188, 10.1158/2159-8290.CD-16-1223 Gettinger, 2017, Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer, Cancer Discov, 7, 1420, 10.1158/2159-8290.CD-17-0593 Spranger, 2015, Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity, Nature, 523, 231, 10.1038/nature14404 Zhao, 2019, Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma, Nat Med, 25, 462, 10.1038/s41591-019-0349-y Brochez, 2017, The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy, Eur J Cancer, 76, 167, 10.1016/j.ejca.2017.01.011 Aspeslagh, 2016, Rationale for anti-OX40 cancer immunotherapy, Eur J Cancer, 52, 50, 10.1016/j.ejca.2015.08.021 Buchan, 2018, The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy, Blood, 131, 39, 10.1182/blood-2017-07-741025 Willoughby, 2017, Ox40: structure and function – what questions remain?, Mol Immunol, 83, 13, 10.1016/j.molimm.2017.01.006 Moran, 2016, Immunotherapy expands and maintains the function of high-affinity tumor-infiltrating CD8 T cells in situ, J.i., 197, 2509 Souza, 1999, Expression of lymphocyte-endothelial receptor-ligand pairs, alpha 4beta 7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease, Gut, 45, 856, 10.1136/gut.45.6.856 Imura, 1996, The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells, J Exp Med, 183, 2185, 10.1084/jem.183.5.2185 Taylor, 2002, In vitro and in vivo activities of OX40 (CD134)-IgG fusion protein isoforms with different levels of immune-effector functions, J Leukoc Biol, 72, 522, 10.1189/jlb.72.3.522 Kawamata, 1998, Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2- and TRAF5-mediated NF-kappaB activation, J Biol Chem, 273, 5808, 10.1074/jbc.273.10.5808 Arch, 1998, 4-1BB and Ox40 Are Members of a Tumor Necrosis Factor (TNF)-Nerve Growth Factor Receptor Subfamily That Bind TNF Receptor-Associated Factors and Activate Nuclear Factor κB, Mol Cell Biol, 18, 558, 10.1128/MCB.18.1.558 Rogers, 2001, Ox40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells, Immunity, 15, 445, 10.1016/S1074-7613(01)00191-1 Song, 2005, Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion, Immunity, 22, 621, 10.1016/j.immuni.2005.03.012 Chao, 2018, Unlocking the complexities of tumor-associated regulatory T cells, J.i., 200, 415 Zhang, 2018, Ox40 costimulation inhibits FOXP3 expression and Treg induction via BATF3-Dependent and independent mechanisms, Cell Rep, 24, 607, 10.1016/j.celrep.2018.06.052 Burocchi, 2011, Intratumor OX40 stimulation inhibits IRF1 expression and IL-10 production by Treg cells while enhancing CD40L expression by effector memory T cells, Eur J Immunol, 41, 3615, 10.1002/eji.201141700 Bulliard, 2014, Ox40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy, Immunol Cell Biol, 92, 475, 10.1038/icb.2014.26 Piconese, 2008, Ox40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection, J Exp Med, 205, 825, 10.1084/jem.20071341 Stüber, 1996, The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response, J Exp Med, 183, 979, 10.1084/jem.183.3.979 Stüber, 1995, Cross-Linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells, Immunity, 2, 507, 10.1016/1074-7613(95)90031-4 Kopf, 1999, OX40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL responses after virus infection, Immunity, 11, 699, 10.1016/S1074-7613(00)80144-2 Metzger, 2016, ICOS Promotes the Function of CD4 + Effector T Cells during Anti-OX40–Mediated Tumor Rejection, Cancer Res, 76, 3684, 10.1158/0008-5472.CAN-15-3412 Chen, 1999, Ox40-ligand has a critical costimulatory role in dendritic cell:T cell interactions, Immunity, 11, 689, 10.1016/S1074-7613(00)80143-0 Ohshima, 1997, Expression and function of OX40 ligand on human dendritic cells, J Immunol, 159, 3838, 10.4049/jimmunol.159.8.3838 Marabelle, 2013, Depleting tumor-specific Tregs at a single site eradicates disseminated tumors, J Clin Invest, 123, 2447, 10.1172/JCI64859 Ramser, 2018, High OX40 expression in recurrent ovarian carcinoma is indicative for response to repeated chemotherapy, BMC Cancer, 18, 425, 10.1186/s12885-018-4339-0 Petty, 2002, Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134), Am J Surg, 183, 512, 10.1016/S0002-9610(02)00831-0 Martins, 2018, Could OX40 agonist antibody promote activation of the anti-tumor immune response in gastric cancer?, J Surg Oncol, 117, 840, 10.1002/jso.25001 Ohmura, 2019, Activation of central/effector memory T cells in advanced gastric cancer patients treated with antiprogrammed death-1 antibody, JCO, 37, 54, 10.1200/JCO.2019.37.4_suppl.54 Sarff, 2008, Ox40 (CD134) expression in sentinel lymph nodes correlates with prognostic features of primary melanomas, Am J Surg, 195, 621, 10.1016/j.amjsurg.2007.12.036 Reuter, 2015, Immunostimulation by OX40 ligand transgenic Ewing sarcoma cells, Front Oncol, 5, 242, 10.3389/fonc.2015.00242 Dannull, 2005, Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand, Blood, 105, 3206, 10.1182/blood-2004-10-3944 Kvarnhammar, 2019, The CTLA-4 X OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation, J Immunother Cancer, 7, 10.1186/s40425-019-0570-8 Oberst, 2018, Potent immune modulation by MEDI6383, an engineered human OX40 ligand IgG4P Fc fusion protein, Mol Cancer Ther, 17, 1024, 10.1158/1535-7163.MCT-17-0200 Weinberg, 2000, Engagement of the OX-40 receptor in vivo enhances antitumor immunity, J Immunol, 164, 2160, 10.4049/jimmunol.164.4.2160 Maxwell, 2000, Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion, J Immunol, 164, 107, 10.4049/jimmunol.164.1.107 Redmond, 2014, Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity, Cancer Immunol Res, 2, 142, 10.1158/2326-6066.CIR-13-0031-T Zippelius, 2015, Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment, Cancer Immunol Res, 3, 236, 10.1158/2326-6066.CIR-14-0226 Polesso, 2019, Late-Stage tumor regression after PD-L1 blockade plus a concurrent OX40 agonist, Cancer Immunol Res, 7, 269, 10.1158/2326-6066.CIR-18-0222 Antonioli, 2016, Anti-CD73 in cancer immunotherapy: awakening new opportunities, Trends in Cancer, 2, 95, 10.1016/j.trecan.2016.01.003 Virani, 2018, Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer, Cancer Lett, 425, 174, 10.1016/j.canlet.2018.03.027 Shrimali, 2017, Concurrent PD-1 blockade negates the effects of OX40 agonist antibody in combination immunotherapy through inducing T-cell apoptosis, Cancer Immunol Res, 5, 755, 10.1158/2326-6066.CIR-17-0292 Messenheimer, 2017, Timing of PD-1 blockade is critical to effective combination immunotherapy with Anti-OX40, Clin Cancer Res, 23, 6165, 10.1158/1078-0432.CCR-16-2677 Curti, 2013, Ox40 is a potent immune-stimulating target in late-stage cancer patients, Cancer Res, 73, 7189, 10.1158/0008-5472.CAN-12-4174 El-Khoueiry, 2017, The relationship of pharmacodynamics (PD) and pharmacokinetics (pK) to clinical outcomes in a phase I study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600), JCO, 35, 3027, 10.1200/JCO.2017.35.15_suppl.3027 Glisson, 2018, 1152PSafety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors, Ann Oncol, 29, 10.1093/annonc/mdy288.025 Spira, 2018, 1149PSafety, tolerability, and pharmacokinetics of the OX40 agonist ABBV-368 in patients with advanced solid tumors, Ann Oncol, 29, 10.1093/annonc/mdy288.022 Bell, 2018, Neoadjuvant anti-OX40 (MEDI6469) prior to surgery in head and neck squamous cell carcinoma, JCO, 36, 6011, 10.1200/JCO.2018.36.15_suppl.6011 Infante, 2016, A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors, JCO, 34, 101, 10.1200/JCO.2016.34.15_suppl.101 Infante, 2016, ENGAGE-1: a first in human study of the OX40 agonist GSK3174998 alone and in combination with pembrolizumab in patients with advanced solid tumors, JCO, 34, TPS3107, 10.1200/JCO.2016.34.15_suppl.TPS3107 Hamid, 2018, 1184PPharmacodynamic (PD) changes in tumors and peripheral blood T cell receptor (TCR) repertoire in a phase I study combining OX40 (PF-04518600) and 4-1BB (utomilumab) agonistic monoclonal antibodies (mAbs), Ann Oncol, 29, 10.1093/annonc/mdy288.057